• Skip to primary navigation
  • Skip to main content
  • Skip to footer
Exopharm

Exopharm

  • Home
  • Products
  • Partnering
  • Science
  • Resources
    • ASX Announcements
    • Investor Information
    • News & Articles
  • About Us
    • Our Values
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
    • Careers
  • Contact

ASX Announcements

CY 2022 ASX Announcements

May

30/05/2022  Business Update

April

29/04/2022  Exopharm Ltd – March 2022 Quarterly Activities Report and Appendix 4C

 

 


CY 2021 ASX Announcements

November

16/11/2021   Exopharm to Present at Key Exosome Industry Event

October

27/10/2021  Quarterly Activities Report and Appendix 4C

26/10/2021  2021 AGM Notice of Meeting and Proxy

26/10/2021  2021 AGM Letter to Shareholders and Proxy

September

30/09/2021  Appointment of Company Secretary

27/09/2021  Exopharm LEAP Technology – Further Step Towards US Patent

08/09/2021 Exopharm LEAP Technology – Second Commercial Collaboration

03/09/2021  Change of Director’s Interest Notice – EM

01/09/2021  Change of Director’s Interest Notice – JW

01/09/2021  Change of Director’s Interest Notice – ID

01/09/2021  Cleansing Notice

01/09/2021  Application for quotation of securities – EX1

01/09/2021  Date of Annual General Meeting

01/09/2021  Initial Director’s Interest Notice – JK

August

31/08/2021  Dr Jenn King joins Exopharm Board

30/08/2021  Appendix 4G and Corporate Governance Statement

30/08/2021  FY2021 Appendix 4E and Annual Report 

26/08/2021  Science Webinar – Overcoming the Nucleic Acid Delivery Challenge

20/08/2021  Investor Webinar Presentation

02/08/2021  Notification regarding unquoted securities

July

27/07/2021  Quarterly Activities Report and Appendix 4C

02/07/2021  Partnering & Licensing Focus Continues

June

30/06/2021  Investor Presentation

03/06/2021  Exopharm LEAP Exosome Technology Granted 1st National Patent

May

06/05/2021  Appendix 2A

April

30/04/2021  Change in substantial holding – ID

30/04/2021  Cleansing Notice

30/04/2021  Appendix 2A

20/04/2021  Proposed issue of Securities – EX1

20/04/2021  Exopharm Receives Firm Commitments to Raise $12 million

16/04/2021  Investor Presentation – Delivering Transformative Medicines

16/04/2021  Quarterly Activities Report and Appendix 4

15/04/2021  Trading Halt

08/04/2021  Exopharm Shareholder Update – Revenue Focus in 2021 

08/04/2021  Appendix 3G

06/04/2021  LEAP Technology- Advanced EV Medicines from Blood Components

06/04/2021  Positive PLEXOVAL II Phase 1 Clinical Trial Results

01/04/2021  Securities Trading Policy 

01/04/2021  Preclinical Data from Osteoarthritis Animal Study

 

February

26/02/2021  Appendix 4D and Half Year Financial Report

26/02/2021  Securities Trading Policy

16/02/2021  Exopharm presents at Bio CEO & Investor Digital Conference

10/02/2021  Change of Director’s Interest Notices – JW and ID

09/02/2021  Substantial Shareholder notices – amendment

08/02/2021  Response to ASX Price and Volume Query

January

29/01/2021  Exopharm Quarterly Activities Report and Appendix 4C

21/01/2021  Progress Points To Partnering Readiness

05/01/2021  Initial Director’s Interest Notice – EM

05/01/2021  Final Director’s Interest Notice – DP

05/01/2021  Exopharm Board Changes

04/01/2021  Change in substantial holding

04/01/2021  Becoming a substantial holder

04/01/2021  Lapse of Performance Rights


CY 2020 ASX Announcements

December

30/12/2020   Response to ASX Price and Volume Query

23/12/2020   Change of Director’s Interest Notice

22/12/2020   Shareholder Update

18/12/2020   Appendix 2A

11/12/2020   Release of Securities from 24 Month Escrow

02/12/2020   Change of Director’s Interest Notice

02/12/2020   Cleansing Notice

02/12/2020   Appendix 2A

November

30/11/2020   Results of Meeting

13/11/2020   Change of Registered Office Address

11/11/2020   Exopharm to Present at Key Exosome Industry Event

09/11/2020   Appendix 2A, Appendix 3G and Cleansing Notice

October

29/10/2020   Letter to Shareholders – Annual General Meeting

29/10/2020   Notice of Annual General Meeting/Proxy Form

29/10/2020   Results of Extraordinary General Meeting

27/10/2020   September Quarterly Report and Appendix 4C

22/10/2020   Plexoval II First Dosing and $2.1m R&D Rebate Received

06/10/2020   Annual General Meeting Date and Director Nominations

September

24/09/2020   Letter to Shareholders

24/09/2020   Notice of Extraordinary General Meeting/Proxy Form

18/09/2020   Shareholder Update: Investor Deck

17/09/2020   Change in Substantial Holding

15/09/2020   Proposed Issue of Securities

15/09/2020   Appointment of Manufacturing Expert & Corporate Advisor

14/09/2020   Annual Report

09/09/2020  Cleansing Notice

08/09/2020  Appendix 2A

August

27/08/2020   Proposed Issue of Securities

27/08/2020   Proposed Issue of Securities

27/08/2020   Exopharm Raises $10M in Well-supported Placement

26/08/2020   Appendix 4G and Corporate Governance Statement FY 2020

26/08/2020   Appendix 4E – Preliminary Final Report for Year Ended 30 June 2020

21/08/2020   Trading Halt Announcement

21/08/2020   Investor Presentation

19/08/2020   Shareholder Update

July

30/07/2020   June 2020 Quarterly Activities Report and Appendix 4C

22/07/2020   Shareholder Update

21/07/2020   Monsoon Communications Morning Twilight Briefing Webinar

June

16/06/2020   Company Secretary and services update

12/06/2020   Top 20 Shareholders Report 

12/06/2020   Additional IP empowers Exopharm’s engineered exosome pipeline

May

28/05/2020   Shareholder Update and Webinar

25/05/2020   Plexaris product engineered to deliver anti-cancer drug

April

24/04/2020   March 2020 Appendix 4C and Quarterly Report

01/04/2020   Plexoval Update

March

26/03/2020    Shareholder Update

05/03/2020   Investor Deck

February

24/02/2020   Statement clarification

20/02/2020   APPENDIX 4D – Interim Financial Report for the half year to 31 December 2019

20/02/2020   Cevaris testing shows positive results in bladder control model

19/02/2020   Cevaris testing shows positive results in models of erectile dysfunction

14/02/2020   Media Release: Erectile Dysfunction a Potential Target for Exopharm’s Exosomes

12/02/2020   Independent Plexaris and Cevaris testing shows positive and unique results

10/02/2020   Shareholder Update. Exopharm in 2020. News, Deals and Clinical Trials

05/02/2020   Investor Deck

January

29/01/2020   December 2019 Quarterly Activities Report and Appendix 4C

28/01/2020   Plexoval Update – World First Human Clinical Trials


CY 2019 ASX Announcements

November

25/11/2019   Key Management Contracts

18/11/2019   Results of AGM Meeting 2019

14/11/2019   Development Program Update

01/11/2019   Investor Deck, November 2019

October

28/10/2019   Appointment of Chief Commercial Officer

25 /10/2019  Shareholder Newsletter – October

25/10/2019   Quarterly 4c

17/10/2019   Notice of Annual General Meeting

17/10/2019   Annual Report

16/10/2019   Notice of Change of Interests of Substantial Holder

September

16-09-2019   Change of Director’s Interest Notice – Appendix 3Y

16/09/2019   Issue of Shares and Appendix 3B

09/09/2019   Results of General Meeting

August

30/08/2019   Appendix 4E and Annual Financial Report FY 2019

30/08/2019   Appendix 4G and Corporate Governance Statement FY 2019

26/08/2019   Plexoval Exosome Wound Healing Human Study Starts

19/08/2019   Appendix 3Y. Change of Director’s Interest Notice

19/08/2019   Appendix 3B. New Issue Announcement

16/08/2019   Closure of Offer Under the Share Purchase Plan

13/08/2019   Application for Quotation of Additional Securities and Agreement

08/08/2019   Notice of General Meeting

01/08/2019   Issue of Placement Shares

July

29/07/2019   EX1 ASX Announcement – Upcoming Release of Shares from Escrow

25/07/2019   Share Purchase Plan (SPP) Offer Document

25/07/2019   Cleansing Statement – Notice under ASIC Class Order [CO 09/425]

25/07/2019   Exopharm Appendix 4C – June Quarter

24/07/2019   Investor Deck Placement and Share Purchase Plan

24/07/2019   Share Placement and Share Purchase Plan Announcement

22/07/2019   Exopharm Secures Ethics Approval for the Plexoval Clinical Trial

22/07/2019   Trading Halt

19/07/2019   Appendix 3B New Issue Announcement

05/07/2019   Escrow Release

May

23/05/2019   Upcoming Release of Shares from Escrow

22/05/2019   Acceleration of Development Activities

April

30/04/2019   March 2019 Quarterly Activities Report and Appendix 4C

09/04/2019   Investor Presentation

01/04/2019   April 2019 Market Update

March

27/03/2019   Explainer: The critical bottleneck of exosome isolation and the power of Exopharm’s LEAP technology

February

21/02/2019   Dec 2018 Half-Yearly Report and Appendix 4D

05/02/2019   Positive outcomes from initial animal studies of Plexaris and Exomeres

January

31/01/2019   January 2019 Quarterly Cash Flow Report

31/01/2019   December 2018 Quarterly Activities Report


CY 2018 ASX Announcements

December

28/12/2018   Investor Deck

28/12/2018   Notice of Initial Substantial Holder

18/12/2018   Initial Director Interests x 3

18/12/2018   Closes Initial Public Offering Fully Subscribed and Lists on the ASX

14/12/2018   Capital Structure and Restricted Securities

14/12/2018   Securities Trading Policy

14/12/2018   Updated Pro-Forma and Commitments

14/12/2018   Financial Statements – Year Ended 30 June 2018

14/12/2018   Financial Statements – Year Ended 30 June 2017

14/12/2018   Financial Statements – Year Ended 30 June 2016

14/12/2018   Constitution

14/12/2018   Prospectus

14/12/2018   Appendix 1A and Information Form and Checklist

14/12/2018   Top 20 Holders

14/12/2018   Distribution Schedule

14/12/2018   ASX Notice – Admission to the Official List

Join the Exopharm Mailing List

Join the Exoparm mailing List and receive occasional updates and important information about our work.

Footer

Resources

  • ASX Announcements
  • Investor Information
  • Board of Directors
  • News & Articles

Information

  • Contact
  • Partnering
  • Join Our Mailing List
  • Privacy, Terms and Conditions
  • Facebook
  • LinkedIn
  • Twitter
  • Vimeo
Copyright © 2022 · Exopharm · ACN 163 765 991 · info@exopharm.com
Level 17/31 Queen St, Melbourne VIC Australia 3000 · P: +61 (0)3 9111 0026 ·

Web Design by Mallee Blue Media
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
Cookie SettingsAccept
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Others
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
SAVE & ACCEPT